Steven James

Steven P.
James is currently Chairman at Soteria Therapeutics, Inc. and Soteria Biotherapeutics, Inc., Director at Ventus Therapeutics, Inc., Ventus Therapeutics U.S., Inc., and Lyterian Therapeutics, Inc. since 2023, and Trustee at Middlebridge School.
Former roles include President, Chief Executive Officer & Director at Labrys Biologics, Inc. from 2012 to 2014; President & Chief Executive Officer at KAI Pharmaceuticals, Inc. from 2004 to 2012; Chairman at Antiva Biosciences, Inc. from 2015 to 2023; Independent Director at Cascadian Therapeutics LLC from 2015 to 2018; Lead Independent Director at OCERA Therapeutics LLC from 2014 to 2017; Independent Director at Allakos, Inc. from 2016 to 2025; Senior Vice President-Commercial Operations at Exelixis, Inc. from 2003 to 2004; Executive Chairman, President & CEO at Pionyr Immunotherapeutics, Inc.; Director at Chrono Therapeutics, Inc., Armetheon, Inc., Ocera, Inc.; Principal at Eli Lilly & Co. and California Biotechnology, Inc.; VP-Business Development & General Manager at Lifecore Biomedical, Inc.; Vice President-Business Development at Ionis Pharmaceuticals, Inc.; and Chief Business Officer at Sunesis Pharmaceuticals, Inc. Education includes undergraduate studies at Brown University and graduate studies at Kellogg School of Management.